SHCS Tables
We thank Abbott, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme Chibret and ViiV Healthcare, for funding the elaboration and publication of following tables.
Updated in November 2011
Demographical characteristics
1 Cumulative number of participants by type of care provider, number and %
2 Cumulative number of participants by center, number and %
3 Recruitment by center and year, number and % *
*Center name hidden
4 Participants under follow-up (i.e. seen in the respective year), number and % *
*Center name hidden
5 Cumulative number of participants by age, sex, ethnicity and transmission category, number and % (situation at 31.12.2010) *
*Center name hidden
6 Recruitment 2010, by age, sex, ethnicity, transmision category, number and % *
*Center name hidden
7 Participants under follow-up in 2010 by age, sex, ethnicity, transmission category, number (%) *
*Center name hidden
Clinical characteristics
8 Recruitements by CDC/CD4 stage and year, number (%)
9 Participants under follow-up by CDC/CD4 stage and year, number (%)
10 The five most frequent AIDS defining events from the four preceding years, number of diagnoses per year, number (%)
11 Deaths during recent years, by CDC stage , number (%)
ANTIRETROVIRAL TREATMENT
12 Treatment status at recruitment, by CD4 and year, number (%)
13 Treatment status at recruitment, by HIV viral load and year, number (%)
14 Treatment status of participants under follow-up, by CD4 and year, number (%) *
* At the first CD4 assessment of the year
15 Treatment status of participants under follow-up, by HIV viral load and year, number (%) *
15 Treatment status of participants under follow-up, by HIV viral load and year, number (%) *
* At the first viral load assessment of the year
16 Participants under treatment by first, second and third regimen, number (%)
17 The five most frequent regimens at a reference date, number
18 The five most frequent initial regimens, by year of prescription, number *
* Data from the last year not yet complete
19 The five most frequent second-line regimens, by year of prescription, number *
* Data from the last year not yet complete
20 The four most frequently discontinued regimens in 2007, by reason, number
20 The four most frequently discontinued regimens in 2007, by reason, number
21 The four most frequently discontinued regimens in 2008, by reason, number
22 The four most frequently discontinued regimens in 2009, by reason, number
23 The four most frequently discontinued regimens in 2010, by reason, number
23 The four most frequently discontinued regimens in 2010, by reason, number
Hepatitis B
24 Status of HBV infection of participants under follow-up having a HBV screening result, by reference date
Hepatitis C
25 Status of HCV infection of participants under follow-up having an anti-HCV screening result, by reference date, number (%)
26 the most frequent HCV genotypes among participants under follow-up with a replicating HCV infection, by reference date, number (%)
27 HCV treatment status of participants under follow-up with a history of replicating HCV, by reference date, number
